Progress in the treatment of liver cancer with portal vein thrombosis based on TACE

doi:10.3877/cma.j.issn.2095-5782.2024.01.011

Abstract

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Patients usually are diagnosed in the middle/advanced stage of HCC and more than half of the patients are accompanied by portal vein tumor thrombosis (PVTT). Without relevant intervention and treatment, the median survival period is about 2.7 months. There is no consensus in China on the choice of treatment methods for these patients. Traditional treatment methods, such as surgical treatment, liver transplantation, radiation therapy and targeted therapy still have unsatisfactory results. With the development of interventional treatment, the combined treatment based on transcatheter arterial chemoembolization (TACE) has shown significant efficacy. In this paper, the clinical diagnosis and pathological classification of hepatocellular carcinoma with portal vein tumor thrombosis and the research progress of TACE based combined with other therapy methods are summarized systematically, so as to provide reference for future clinical work.

Key words: Hepatocellular carcinoma, Portal vein cancer thrombosis, Transcatheter arterial chemoembolization intervention treatment

Haoran Cui, Junpeng Gu, Weixin Ren. Progress in the treatment of liver cancer with portal vein thrombosis based on TACE[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(01): 64-69.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2024.01.011

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2024/V12/I01/64

References 41

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71(3)：209-249.
[2]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2022年版)[J].肝癌电子杂志, 2022, 9(1): 1-22.
[3]	王木子, 刘宏. 肝细胞癌合并门静脉癌栓诊疗进展[J]. 临床与病理杂志, 2023, 43(4): 827-835.
[4]	李玮, 王雯, 齐梦剑, 等. 肝癌合并门静脉癌栓局部治疗进展[J]. 中国实用外科杂志, 2023, 43(5): 591-596.
[5]	龚高全, 王小林, 王建华, 等. 肝癌门静脉支架植入术对门静脉压力的影响[J]. 介入放射学杂志, 2007, 16(3): 159-161.
[6]	程树群, 蔡建强, 陈敏山, 等. 肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J]. 临床肝胆病杂志, 2019, 35(4): 737-743.
[7]	李红学, 刘连凤, 李航, 等. 超声技术在门静脉癌栓诊治中的研究进展[J]. 广西医科大学学报, 2020, 37(11): 2088-2091.
[8]	Chen J, Zhu J, Zhang C, et al. Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis[J]. Eur Radiol, 2020, 30(5): 2871-2880.
[9]	Seok JB, Min JL, Hee JY, et al. How to best detect portal vein tumor thrombosis in patients with hepatocellular carcinoma meeting the milan criteria: gadoxetic acid-enhanced MRI versus contrast-enhanced CT[J]. Liver Cancer, 2020, 9(3): 293-307.
[10]	李宏, 徐小虎, 彭进, 等. CT门静脉造影三维重建诊断门静脉癌栓的价值[J]. 中国CT和MRI杂志, 2022, 20(12): 101-102.
[11]	Li Y, Zhang Y, Fang Q, et al. Radiomics analysis of [¹⁸F] FDG PET/CT for microvascular invasion and prognosis prediction in very-early and early-stage hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2021, 48(11): 2599-2614.
[12]	Deng ZJ, Li L, Teng YX, et al. Treatments of hepatocellular carcinoma with portal vein tumor thrombus: current status and controversy[J]. J Clin Transl Hepatol, 2022, 10(1): 147-158.
[13]	中国医师协会肝癌专业委员会会议. 中国肝癌合并门静脉癌栓诊治指南(2021年版)[J]. 中华医学杂志, 2022, 102(4): 243-254.
[14]	Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: a concise review and comparison of current guidelines: 2022 update[J]. Biosci Trends, 2022, 16(1): 20-30.
[15]	Arno DF, Erwin H, Stijn HV, et al. Clinical management of chronic hepatitis B: a concise overview[J]. United European Gastroenterol J, 2022, 10(1): 115-123.
[16]	Lin DX, Zhang QY, Li X, et al. An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus[J]. Journal of Cancer Research and Clinical Oncology, 2011, 137(1): 139-149.
[17]	奉建祁, 王志明. 中晚期原发性肝癌治疗的新进展[J]. 中国普通外科杂志, 2021, 30(7): 847-857.
[18]	Liu S, Li H, Guo L, et al. Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion[J]. Oncologist, 2019, 24(4): 513-520.
[19]	Zhang H, Cao G, Ren W, et al. Vascular normalization therapy with targeted localized vessel bevacizumab infusion in hepatocellular carcinoma after transarterial chemoembolization failure[J]. Ann Palliat Med, 2021, 10(8): 9149-9156.
[20]	Yuan J, Yin X, Tang B, et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study[J]. Biomed Res Int, 2019, 2019: 2141859.
[21]	Zhang X, Wang K, Wang M, et al. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(17): 29416-29427.
[22]	林晓纯, 萧聪勤, 林坤鹏. 阿帕替尼联合肝动脉化疗栓塞术治疗肝癌合并门静脉癌栓的Meta分析[J]. 广州医科大学学报, 2022, 50(4): 34-41.
[23]	韩瑞瑞, 张锦, 马立翠, 等.原发性肝癌合并门静脉癌栓免疫治疗进展[J]. 肝脏, 2021, 26(2): 213-216.
[24]	张菊花, 陈珑, 刘宇杰, 等.原发性肝癌伴门脉癌栓患者行局部治疗联合PD-1治疗的不良反应观察护理[J]. 循证医学, 2020, 20(6): 351-356.
[25]	曹俊宁, 张雯雯, 赵海涛, 等.基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J].肝癌电子杂志, 2021, 8(2): 6-15.
[26]	Zou X, Xu Q, You R, et al. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features[J]. Cancer Medicine, 2023, 12(10): 11315-11333.
[27]	王亚运, 胡欢, 王世垚, 等. 三维适形放疗联合TACE治疗肝癌伴门静脉癌栓的有效性与安全性的Meta分析[J]. 西北国防医学杂志, 2018, 39(11): 704-710.
[28]	彭辉, 肖仁斌, 王江涛, 等. 经导管植入¹²⁵I放射性粒子治疗肝癌伴门静脉癌栓的效果[J]. 中国当代医药, 2019, 26(26): 82-84.
[29]	Han DH, Joo DJ, Kim MS, et al. Living donor liver transplantation for advanced hepatocellular carcinoma with portal vein tumor thrombosis after concurrent chemoradiation therapy[J]. Yonsei Med J, 2016, 57(5): 1276-1281.
[30]	梁军, 葛乃健, 过欣来, 等. 经皮门脉射频消融导管消融联合肝动脉化疗栓塞治疗肝癌伴Ⅲ型门静脉癌栓的临床疗效[J].肝胆外科杂志, 2020, 28(5): 345-348.
[31]	陆正华, 沈锋, 袁国新, 等. 肝癌门静脉癌栓的经皮激光消融治疗[J]. 中华外科杂志, 2004, 42(9): 57-60.
[32]	谌浩, 刘曦, 罗小平, 等. 经导管动脉化疗栓塞术联合高强度聚焦超声在原发性巨块型肝癌合并门脉癌栓治疗中的疗效评估[J]. 重庆医科大学学报, 2021, 46(1): 101-106.
[33]	韦伟, 关利君.TACE联合微波消融与联合¹²⁵I放射性粒子植入治疗不可切除肝癌合并门静脉癌栓疗效比较[J]. 介入放射学杂志, 2022, 31(9): 889-893.
[34]	Sun B, Zhang W, Chen L, et al. The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus[J]. Abdom Radiol (NY), 2022, 47(2): 858-868.
[35]	Pan Y, Wang R, Hu D, et al. Comparative safety and eflicacy of moleculer tageted druss. immune checkpoint in hibitors, hepstic atteral infusion chemotherapy and their combinations in adwaneed hepitocellular carcinoma, findings from advances in landmark trials[J]. Front Biosci ( Landmark Ed), 2021, 26(10): 873-881.
[36]	Long GB, Xiao CW, Zhao XY, et al. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis[J]. Medicine (Baltimore), 2020, 99(26): e20745.
[37]	柯映平, 叶绍光, 卢舜彬. 肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗对肝细胞癌伴门静脉癌栓患者的近期疗效[J]. 中国医药科学, 2022, 12(16): 156-159.
[38]	Yamakado K, Tanaka N, Nakatsuka A, et al. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein[J]. J Hepatol, 1999, 30(4): 660-668.
[39]	李红彬, 焦德超, 马波, 等. 门静脉支架同步¹²⁵I粒子条植入序贯经导管动脉化疗栓塞术治疗肝癌伴门静脉癌栓[J]. 中国医学影像技术, 2021, 37(3): 406-410.
[40]	周腾超, 田壮博, 龙林. 双导向技术引导下¹²⁵I粒子条联合门静脉支架植入术序贯经导管动脉化疗栓塞术治疗原发性肝细胞癌合并门静脉癌栓的有效性及安全性[J]. 肝癌电子杂志, 2022, 9(4): 52-58.
[41]	Zhang ZH, Hou SN, Yu JZ, et al. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: a propensity-score analysis[J]. Front Oncol, 2023, 12: 1086095.

Please choose a citation manager

Content to export